This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
If You Invested $1000 in Stryker a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
The Zacks Analyst Blog Highlights NVIDIA, Advanced Micro Devices, Stryker, Canadian National Railway and Target
by Zacks Equity Research
NVIDIA, Advanced Micro Devices, Stryker, Canadian National Railway and Target are part of the Zacks top Analyst Blog.
Top Research Reports for NVIDIA, AMD, Stryker & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Advanced Micro Devices, Inc. (AMD) and Stryker Corporation (SYK).
Stryker's (SYK) New Camera Platform to Improve Surgery Outcomes
by Zacks Equity Research
Stryker's (SYK) latest camera platform is likely to enhance the surgical experience across specialties.
Strength Seen in Lantheus Holdings (LNTH): Can Its 6.4% Jump Turn into More Strength?
by Zacks Equity Research
Lantheus Holdings (LNTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Stryker (SYK) Gets FDA 501k Clearance for Pangea Trauma Systems
by Zacks Equity Research
Stryker's (SYK) Pangea systems will boost the company's Trauma business unit following a complete launch. SYK plans to present the new system at the Annual Orthopaedic Trauma Association meeting.
HAE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Perrigo (PRGO) Down 11.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Add Stryker (SYK) Stock to Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
HAE vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Shockwave Medical (SWAV) Q2 Earnings Miss, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Stryker (SYK) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Stryker (SYK) Q2 Earnings Beat Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.
Stryker (SYK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 6.72% and 3.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Q2 Earnings Meet Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 0% and 1.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics
by Zacks Equity Research
Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics are part of the Zacks Industry Outlook article.
4 Medical Product Stocks to Buy Amid Recovering Prospects
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. ABT, SYK, ZBH and HAE are well poised to gain from the favorable factors.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.
HAE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Stryker (SYK) Launches Q Guidance System for Cranial Surgeries
by Zacks Equity Research
Stryker (SYK) launches its Q Guidance system with Cranial Guidance software, offering surgeons a comprehensive planning and guidance solution for complex cranial procedures.
Stryker (SYK) Launches Autonomous Guidance System for Surgeries
by Zacks Equity Research
Stryker's (SYK) fully autonomous Ortho Q Guidance system offers smart and streamlined workflow, leading to enhanced procedural speed and efficiency.
Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
Stryker (SYK) Stock Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
HLN vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HLN vs. SYK: Which Stock Is the Better Value Option?
Stryker (SYK) Moves 4.2% Higher: Will This Strength Last?
by Zacks Equity Research
Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.